Co-Authors
This is a "connection" page, showing publications co-authored by Dongfeng Qu and William Berry.
Connection Strength
0.460
-
Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. J Oncol. 2019; 2019:6402925.
Score: 0.171
-
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer. Cancer Lett. 2023 Oct 12; 216437.
Score: 0.057
-
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 2018 09 01; 143(5):1162-1175.
Score: 0.039
-
Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury. Sci Rep. 2016 11 23; 6:37667.
Score: 0.035
-
Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. Cancer Res. 2016 07 15; 76(14):4090-9.
Score: 0.034
-
Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget. 2015 Aug 21; 6(24):20327-44.
Score: 0.033
-
DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget. 2015 Feb 10; 6(4):2193-205.
Score: 0.031
-
Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer. 2014 May 06; 13:103.
Score: 0.030
-
Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism. PLoS One. 2013; 8(11):e80304.
Score: 0.029